Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney
disease (CKD). Both conditions are rising in incidence as well as prevalence, creating poor …

The causes of excess cardiovascular mortality associated with chronic kidney disease
(CKD) have been attributed in part to the CKD-mineral bone disorder syndrome (CKD-MBD) …

Interventions To Attenuate Vascular Calcification Progressio... : Journal of the American
Society of Nephrology Interventions To Attenuate Vascular Calcification Progression in Chronic …

Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

Disturbances in phosphate homeostasis are common in patients with chronic kidney
disease. As kidney function declines, circulating concentrations of phosphate and the …

The extracellular domain of transmembrane alpha-Klotho (αKlotho, hereinafter simply called
Klotho) is cleaved by secretases and released into the circulation as soluble Klotho. Soluble …

In chronic kidney disease, vascular calcification, renal osteodystrophy, and phosphate
contribute substantially to cardiovascular risk and are components of CKD–mineral and …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …

Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD)
syndrome is an important contributor to the CKD-associated cardiovascular disease and …

Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …